$
0. 04
0
0%
$
3.52M Market Cap
- P/E Ratio
- Div Yield
1,300 Volume
- Eps
$ 0.04
Previous Close Want to track TDSGF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TDSGF closed today higher at $0.04, an increase of 0% from yesterday's close, completing a monthly increase of 52.1739% or $0.01. Over the past 12 months, TDSGF stock lost -30%.
TDSGF is not paying dividends to its shareholders.
The last earnings report, released on May 27, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0013%, based on the last three reports.
Telo Genomics Corp has completed 1 stock splits, with the recent split occurring on Nov 22, 2019.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
Telo Genomics Corp (TDSGF) FAQ
What is the stock price today?
The current price is $0.04.
On which exchange is it traded?
Telo Genomics Corp is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is TDSGF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 3.52M.
Has Telo Genomics Corp ever had a stock split?
Telo Genomics Corp had 1 splits and the recent split was on Nov 22, 2019.
Telo Genomics Corp Profile
| Biotechnology Industry | Healthcare Sector | John Allen Farlinger CEO | OTC PINK Exchange | 87975M208 CUSIP |
| CA Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges. The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer. Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019. Its headquarters are located in Toronto, Canada.
Contact Information
Address: 555 Richmond Street West
Phone: 416-673-8487
Website: https://www.telodx.com
